Open Access
Vis Cancer Med
Volume 4, 2023
Article Number 6
Number of page(s) 5
Published online 31 May 2023
  1. Worzfeld T, Offermanns S, Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014;13(8):603–621. [CrossRef] [PubMed] [Google Scholar]
  2. Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021;11(7):3262–3277. [CrossRef] [PubMed] [Google Scholar]
  3. Yazdani U, Terman JR. The semaphorins. Genome Biol. 2006;7(3):211. [CrossRef] [PubMed] [Google Scholar]
  4. Rajabinejad M, Asadi G, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, et al. Semaphorin 4A, 4C, and 4D: Function comparison in the autoimmunity, allergy, and cancer. Gene 2020;746; 144637. [CrossRef] [PubMed] [Google Scholar]
  5. Perälä N, Jakobson M, Ola R, Fazzari P, Penachioni JY, Nymark M, et al. Sema4C-Plexin B2 signalling modulates ureteric branching in developing kidney. Differentiation 2011;81(2):81–91. [CrossRef] [PubMed] [Google Scholar]
  6. Maier V, Jolicoeur C, Rayburn H, Takegahara N, Kumanogoh A, Kikutani H, et al. Semaphorin 4C and 4G are ligands of Plexin-B2 required in cerebellar development. Mol Cell Neurosci 2011;46(2):419–431. [CrossRef] [PubMed] [Google Scholar]
  7. Wei J, Yang J, Liu D, Wu M, Qiao L, Wang J, et al. Tumor-associated lymphatic endothelial cells promote lymphatic metastasis by highly expressing and secreting SEMA4C. Clin Cancer Res. 2017;23(1):214–224. [CrossRef] [PubMed] [Google Scholar]
  8. Huang S, Han S, Zhang J, Zhong Z, Wang J. Semaphorin-4C is upregulated in epithelial ovarian cancer. Oncol Lett. 2020;19(4):3333–3338. [PubMed] [Google Scholar]
  9. Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, et al. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. Oncogene 2020;39(5):1049–1062. [CrossRef] [PubMed] [Google Scholar]
  10. Yang J, Zeng Z, Qiao L, Jiang X, Ma J, Wang J, et al. Semaphorin 4C promotes macrophage recruitment and angiogenesis in breast cancer. Mol Cancer Res. 2019;17(10):2015–2028. [CrossRef] [PubMed] [Google Scholar]
  11. Gurrapu S, Pupo E, Franzolin G, Lanzetti L, Tamagnone L, Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018;25(7):1259–1275. [CrossRef] [PubMed] [Google Scholar]
  12. Gurrapu S, Franzolin G, Fard D, Accardo M, Medico E, Sarotto I, et al. Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells. Sci Signal. 2019;12(595): eaav2041. [CrossRef] [PubMed] [Google Scholar]
  13. Wang Y, Qiao L, Yang J, Li X, Duan Y, Liu J, et al. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Cancer Commun. 2021;41(12):1373–1386. [CrossRef] [Google Scholar]
  14. Wang Y, Liu J, Li J, Li H, Li X, Qiao L, et al. Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer. Clin Transl Med. 2021;11(8): e480. [PubMed] [Google Scholar]
  15. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. [CrossRef] [PubMed] [Google Scholar]
  16. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769. [CrossRef] [PubMed] [Google Scholar]
  17. Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer statistics, 2022. CA: A Cancer J Clin. 2022;72(1):7–33. [CrossRef] [PubMed] [Google Scholar]
  18. Jalkanen S, Salmi M. Lymphatic endothelial cells of the lymph node. Nat Rev Immunol. 2020;20(9):566–578. [CrossRef] [PubMed] [Google Scholar]
  19. Wu M, Han L, Shi Y, Xu G, Wei J, You L, et al. Development and characterization of a novel method for the analysis of gene expression patterns in lymphatic endothelial cells derived from primary breast tissues. J Cancer Res Clin Oncol. 2010;136(6):863–872. [CrossRef] [PubMed] [Google Scholar]
  20. Hung YH, Lai MD, Hung WC, Chen LT. Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. Am J Cancer Res. 2022;12(2):713–728. [PubMed] [Google Scholar]
  21. Hou Y, Wang W, Zeng Z, Gan W, Lv S, Li T, et al. High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma. Aging (Albany NY). 2020;12(21):21992–22018. [CrossRef] [PubMed] [Google Scholar]
  22. Ye SM, Han M, Kan CY, Yang LL, Yang J, Ma QF, et al. Expression and clinical significance of Sema4C in esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi Xue Za Zhi 2012;92(28):1954–1958. [PubMed] [Google Scholar]
  23. Jing L, Bo W, Yourong F, Tian W, Shixuan W, Mingfu W. Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells. Sci Rep. 2019;9(1):17727. [CrossRef] [PubMed] [Google Scholar]
  24. Fitzgerald SP. Breast-cancer screening-viewpoint of the IARC working group. New Engl J Med. 2015;373(15):1479. [Google Scholar]
  25. Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer 2020;27(4):621–630. [CrossRef] [PubMed] [Google Scholar]
  26. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7(8):2357–2362. [PubMed] [Google Scholar]
  27. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. 2017;116(4):501–508. [CrossRef] [PubMed] [Google Scholar]
  28. Afzal S, Hassan M, Ullah S, Abbas H, Tawakkal F, Khan MA. Breast cancer; discovery of novel diagnostic biomarkers, drug resistance, and therapeutic implications. Front Mol Biosci. 2022;9:783450 [CrossRef] [PubMed] [Google Scholar]
  29. Li J, Guan X, Fan Z, Ching LM, Li Y, Wang X, et al. Non-invasive biomarkers for early detection of breast cancer. Cancers (Basel). 2020;12(10):2767. [CrossRef] [PubMed] [Google Scholar]
  30. Stavros A, Freitas A, deMello G, Barke L, McDonald D, Kaske T, et al. Ultrasound positive predictive values by BI-RADS categories 3–5 for solid masses: An independent reader study. European Radiol. 2017;27(10):4307–4315. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.